ABSTRACT
The goal of this study is to assess the potential of cultivating plant-based raw materials in Mecklenburg-Vorpommern from the perspective of the pharmaceutical industry and to discuss the factors that could hinder the realization of high-quality cultivation. Procuring high-quality plant-based materials is crucial for the production of plant-based medicines, and the pharmaceutical industry has faced increasing challenges in sourcing these materials in recent years. The methodology involved surveying pharmaceutical companies that are members of the German Pharmaceutical Industry Association and are involved in the fields of homeopathic/anthroposophic medicines and plant-based pharmaceuticals. An online questionnaire was used to collect data. According to the pharmaceutical industry's perspective, there is growing demand for plant-based raw materials from domestic cultivation. Stable supply chains, quality, and reliability are seen as primary advantages over foreign cultivation. Geopolitical conflicts, climate change, and the COVID-19 pandemic have negatively affected the stability of supply chains for imported goods. 73% of companies reported encountering import difficulties multiple times. The majority of pharmaceutical companies can envision increased cooperation with agricultural enterprises in Mecklenburg-Vorpommern. Sustainability in sourcing was already deemed significant by more than two-thirds of the respondents. The study concludes that the importance of sustainable pharmaceutical production, stable supply chains, and high-quality plant-based raw materials will continue to grow. Mecklenburg-Vorpommern provides favorable conditions to meet a portion of the demand. To fully utilize the theoretical potential, close collaboration between the industry, academia, and policymakers is needed, along with minimizing regulatory and bureaucratic barriers for agricultural enterprises.